Patients 0 8 0 8 O
must 9 13 9 13 O
be 14 16 14 16 O
> 17 18 17 18 O
24 19 21 19 21 B-lower_bound
months 22 28 22 28 I-lower_bound
and 29 32 29 32 O
< 33 34 33 34 O
30 35 37 35 37 B-upper_bound
years 38 43 38 43 I-upper_bound
of 44 46 44 46 O
age 47 50 47 50 B-age
when 51 55 51 55 O
registered 56 66 56 66 O
on 67 69 67 69 O
study 70 75 70 75 O

Patients 0 8 76 84 O
must 9 13 85 89 O
have 14 18 90 94 O
evidence 19 27 95 103 O
of 28 30 104 106 O
MIBG 31 35 107 111 B-treatment
uptake 36 42 112 118 O
into 43 47 119 123 O
tumor 48 53 124 129 B-cancer
at 54 56 130 132 O
â‰¥ 57 58 133 134 O
one 59 62 135 138 O
site 63 67 139 143 O
within 68 74 144 150 O
4 75 76 151 152 B-upper_bound
weeks 77 82 153 158 I-upper_bound
prior 83 88 159 164 I-upper_bound
to 89 91 165 167 O
entry 92 97 168 173 O
on 98 100 174 176 O
study 101 106 177 182 O
and 107 110 183 186 O
subsequent 111 121 187 197 O
to 122 124 198 200 O
any 125 128 201 204 O
intervening 129 140 205 216 O
therapy 141 148 217 224 O

Patients 0 8 225 233 O
must 9 13 234 238 O
have 14 18 239 243 O
relapsed 19 27 244 252 B-cancer
neuroblastoma 28 41 253 266 I-cancer
, 41 42 266 267 O
refractory 43 53 268 278 B-cancer
neuroblastoma 54 67 279 292 I-cancer
that 68 72 293 297 O
had 73 76 298 301 O
less 77 81 302 306 O
than 82 86 307 311 O
a 87 88 312 313 O
partial 89 96 314 321 O
response 97 105 322 330 O
to 106 108 331 333 O
standard 109 117 334 342 B-treatment
treatment 118 127 343 352 I-treatment
or 128 130 353 355 O
persistent 131 141 356 366 O
neuroblastoma 142 155 367 380 O
that 156 160 381 385 O
had 161 164 386 389 O
at 165 167 390 392 O
least 168 173 393 398 O
a 174 175 399 400 O
partial 176 183 401 408 O
response 184 192 409 417 O
to 193 195 418 420 O
frontline 196 205 421 430 B-treatment
therapy 206 213 431 438 I-treatment
frontline 214 223 439 448 O
therapy 224 231 449 456 O
with 232 236 457 461 O
> 237 238 462 463 O
3 239 240 464 465 B-lower_bound
residual 241 249 466 474 O
lesions 250 257 475 482 O
on 258 260 483 485 O
end 261 264 486 489 O
- 264 265 489 490 O
induction 265 274 490 499 O
MIBG 275 279 500 504 B-treatment
scan 280 284 505 509 I-treatment

Patients 0 8 510 518 O
who 9 12 519 522 O
have 13 17 523 527 O
bone 18 22 528 532 B-chronic_disease
marrow 23 29 533 539 I-chronic_disease
disease 30 37 540 547 I-chronic_disease
must 38 42 548 552 O
still 43 48 553 558 O
have 49 53 559 563 O
adequate 54 62 564 572 O
bone 63 67 573 577 O
marrow 68 74 578 584 O
function 75 83 585 593 O
to 84 86 594 596 O
enter 87 92 597 602 O
the 93 96 603 606 O
study 97 102 607 612 O

They 0 4 613 617 O
are 5 8 618 621 O
pregnant 9 17 622 630 B-pregnancy
or 18 20 631 633 O
breast 21 27 634 640 O
feeding 28 35 641 648 O

They 0 4 649 653 O
have 5 9 654 658 O
a 10 11 659 660 O
history 12 19 661 668 O
of 20 22 669 671 O
a 23 24 672 673 O
venous 25 31 674 680 B-chronic_disease
or 32 34 681 683 I-chronic_disease
arterial 35 43 684 692 I-chronic_disease
thrombosis 44 54 693 703 I-chronic_disease
that 55 59 704 708 O
was 60 63 709 712 O
not 64 67 713 716 O
associated 68 78 717 727 O
to 79 81 728 730 O
a 82 83 731 732 O
central 84 91 733 740 O
line 92 96 741 745 O

They 0 4 746 750 O
have 5 9 751 755 O
active 10 16 756 762 B-chronic_disease
diarhhea 17 25 763 771 I-chronic_disease

They 0 4 772 776 O
have 5 9 777 781 O
active 10 16 782 788 O
infections 17 27 789 799 O
such 28 32 800 804 O
as 33 35 805 807 O
hepatitis 36 45 808 817 B-chronic_disease
or 46 48 818 820 O
fungal 49 55 821 827 B-chronic_disease
infections 56 66 828 838 I-chronic_disease

They 0 4 839 843 O
have 5 9 844 848 O
had 10 13 849 852 O
an 14 16 853 855 O
allogeneic 17 27 856 866 B-treatment
stem 28 32 867 871 I-treatment
cell 33 37 872 876 I-treatment
transplant 38 48 877 887 I-treatment
( 49 50 888 889 O
received 50 58 889 897 O
stem 59 63 898 902 O
cell 64 68 903 907 O
from 69 73 908 912 O
someone 74 81 913 920 O
else 82 86 921 925 O
) 86 87 925 926 O

They 0 4 927 931 O
have 5 9 932 936 O
had 10 13 937 940 O
previous 14 22 941 949 O
I-131 23 28 950 955 B-treatment
MIBG 29 33 956 960 I-treatment
therapy 34 41 961 968 I-treatment

